A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
מצבים רפואיים
RSV Infection · RSV · Respiratory Syncytial Virus (RSV)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID), Bangkok, Thailand
Contact: Principal Investigator (Napaporn Chantasrisawad, MD)Nakornping Hospital, Chiang Mai, Thailand
Contact: Principal Investigator (Rujirek Kamolrattana, MD)Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
Contact: Principal Investigator (Tavitiya Sudjaritruk, MD)Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
Contact: Principal Investigator (Suchada Ruenglerdpong, MD)Khon Kaen Hospital, Khon Kaen, Thailand
Contact: Principal Investigator (Ussanee Srirompotong, MD)Lampang Hospital, Lampang, Thailand
Contact: Principal Investigator (Pakawadi Vuttipittayamongkol, MD)Lamphun Hospital, Lamphun, Thailand
Contact: Principal Investigator (Sangravee Juhong, MD)Maha Sarakham Hospital, Maha Sarakham, Thailand
Contact: Principal Investigator (Supawan Papakhee, MD)
מובילי המחקר
Enanta Pharmaceuticals, Inc
Study Director
Enanta Pharmaceuticals, Inc